# A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer

> **NCT07076095** · PHASE2 · NOT_YET_RECRUITING · sponsor: **SUNHO（China）BioPharmaceutical CO., Ltd.** · enrollment: 200 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** IBB0979
- **DRUG:** topotecan hydrochloride for injection

## Key facts

- **NCT ID:** NCT07076095
- **Lead sponsor:** SUNHO（China）BioPharmaceutical CO., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-01
- **Primary completion:** 2028-08-01
- **Final completion:** 2031-08-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-07-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07076095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07076095, "A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07076095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*